Skip to content
RushPR News – Lifestyle
Author:
Praxis Precision Medicines, Inc.
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
November 12, 2026
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
November 9, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 4, 2026
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
October 27, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2026
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
July 30, 2026
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
July 7, 2026
1
2
Next Page
→